| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2002 | CA2353193A1 Identifying material from a breast duct |
| 01/24/2002 | WO2002006821A2 Antimicrobial agent |
| 01/24/2002 | WO2002006523A2 Method for detecting pre-disposition to hepatotoxicity |
| 01/24/2002 | WO2002006514A1 Enzyme activated chemotherapy of liver cancer |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006462A2 Methylated nucleotide regulation of upa gene expression |
| 01/24/2002 | WO2002006460A2 Masp-2, a complement-fixing enzyme, and uses for it |
| 01/24/2002 | WO2002006351A1 Drugs or cosmetics |
| 01/24/2002 | WO2002006349A1 Gel compositions containing metronidazole |
| 01/24/2002 | WO2002006340A2 Tetraspan protein and uses thereof |
| 01/24/2002 | WO2002006299A2 Therapeutic uses for aminosterol compounds |
| 01/24/2002 | WO2002006293A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006286A2 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006283A1 Improved preparation of (4r, 5s, 6s)-3-(((2r,3r)-2-((((s)-2-amino-3-methyl-1-oxobutyl)methyl)tetrahydro-3-furanyl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid |
| 01/24/2002 | WO2002006282A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 01/24/2002 | WO2002006281A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006278A1 Oxazolidinone derivatives as antimicrobials |
| 01/24/2002 | WO2002006276A1 Beta3 adrenergic agonists |
| 01/24/2002 | WO2002006275A1 Novel processes for the preparation of 4-phenylpiperidine derivatives |
| 01/24/2002 | WO2002006273A1 Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006270A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | WO2002006268A1 Amino alcohol derivatives |
| 01/24/2002 | WO2002006264A1 Lipid-rich plaque inhibitors |
| 01/24/2002 | WO2002006261A1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 01/24/2002 | WO2002006259A1 Heterocyclic fluoroalkenyl thioethers and the use thereof as pesticides (iv) |
| 01/24/2002 | WO2002006257A1 Heterocyclic fluoroalkenyl thioethers and the use thereof as pesticides (iii) |
| 01/24/2002 | WO2002006256A1 Heterocyclic fluoroalkenyl thioethers (ii) |
| 01/24/2002 | WO2002006255A2 Hydroxy-(piperidin-4-yl-methylamino)-alkyl beta-3 adrenergic receptor antagonists |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006248A2 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 01/24/2002 | WO2002006246A1 Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors |
| 01/24/2002 | WO2002006245A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006241A1 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006225A1 Preventives or remedies for atopic dermatitis |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006221A2 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006218A2 STABILIZED 1α-HYDROXY VITAMIN D |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002006205A1 Method for preparing a fatty substance ester and use thereof in pharmaceutics, cosmetics or food industry |
| 01/24/2002 | WO2002006189A2 Aniline derivatives |
| 01/24/2002 | WO2002005870A2 Kits and compositions supporting intracranial perfusions |
| 01/24/2002 | WO2002005864A1 An implantable or insertable therapeutic agent delivery device |
| 01/24/2002 | WO2002005856A2 Acyclic isoprenoid ether derivatives as chemotherapuetics |
| 01/24/2002 | WO2002005855A1 Pharmaceutical compositions containing dds compounds |
| 01/24/2002 | WO2002005853A2 Compositions containing alpha-2-adrenergic agonist components |
| 01/24/2002 | WO2002005852A1 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 01/24/2002 | WO2002005851A2 Enhancement of the action of central and peripheral nervous system agents |
| 01/24/2002 | WO2002005849A2 Transportation of nucleic acid substances |
| 01/24/2002 | WO2002005848A2 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 01/24/2002 | WO2002005844A2 Protein complex serving as a vehicle for orally administerable medicaments |
| 01/24/2002 | WO2002005842A2 Preventing airway mucus production by administration of egf-r antagonists |
| 01/24/2002 | WO2002005834A2 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions |
| 01/24/2002 | WO2002005832A1 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof |
| 01/24/2002 | WO2002005831A1 Health food useful for preventing liver and biliary dysfunctions containing an alkanoyl l-carnitine and silybum marianum extract |
| 01/24/2002 | WO2002005827A2 Use of natural products in cancer treatment |
| 01/24/2002 | WO2002005826A1 Use of polysulphated cyclodextrins for treating osteoarthritis |
| 01/24/2002 | WO2002005825A1 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders |
| 01/24/2002 | WO2002005824A1 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005823A2 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH |
| 01/24/2002 | WO2002005822A2 Compositions containing therapeutically active components having enhanced solubility |
| 01/24/2002 | WO2002005821A1 Methods for the inhibition of egg production in trematodes |
| 01/24/2002 | WO2002005820A1 Sildenafil citrate solid dispersions having high water solubility |
| 01/24/2002 | WO2002005818A2 Novel method of use of multidrug resistance modulators |
| 01/24/2002 | WO2002005817A1 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence |
| 01/24/2002 | WO2002005816A1 A bioavailable dosage form of loratadine |
| 01/24/2002 | WO2002005815A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | WO2002005814A1 Use of il-8 receptor antagonists in the treatment of virus infections |
| 01/24/2002 | WO2002005813A2 Method for preventing and/or decreasing amyloid production with polycyclic compounds |
| 01/24/2002 | WO2002005812A1 Medicaments for chemotherapeutic treatment of disease |
| 01/24/2002 | WO2002005810A1 Modulation of nitric oxide synthase by pkc |
| 01/24/2002 | WO2002005809A1 Dermal for amino laevulinic acid |
| 01/24/2002 | WO2002005808A1 Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors |
| 01/24/2002 | WO2002005807A1 Treatment of eating disorders using carboxyalkylethers |
| 01/24/2002 | WO2002005806A1 Pharmaceutical compositions comprising capsaicin for the treatment of pruritus ani |
| 01/24/2002 | WO2002005805A1 Method for inducing an estrous cycle and pregnancy in a female mammal |
| 01/24/2002 | WO2002005804A1 Compounds and methods |
| 01/24/2002 | WO2002005802A1 Method of fundamentally treating common cold |
| 01/24/2002 | WO2002005801A2 Compositions containing diacyltartaric salts of (e)-metanicotine |
| 01/24/2002 | WO2002005800A2 Compositions for sustained release of analgesic agents, and methods of making and using the same |
| 01/24/2002 | WO2002005799A2 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 01/24/2002 | WO2002005798A2 Pharmaceutical compositions for treating neurological disorders |
| 01/24/2002 | WO2002005797A2 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia |
| 01/24/2002 | WO2002005796A2 Use of a spla2 inhibitor for the treatment of sepsis |
| 01/24/2002 | WO2002005794A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | WO2002005793A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | WO2002005792A2 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 01/24/2002 | WO2002005791A2 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2002005784A1 A medicinal aerosol formulation |
| 01/24/2002 | WO2002005782A2 Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/24/2002 | WO2002005775A1 Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof, and a metalloproteinase inhibitor |